celecoxib has been researched along with 6-ketoprostaglandin f1 alpha in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamilton, LC; Leach, M; Olbrich, A; Thiemermann, C; Wray, GM | 1 |
| Hamilton, LC; Warner, TD | 1 |
| Catella-Lawson, F; FitzGerald, GA; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF | 1 |
| Chemtob, S; Clyman, RI; Heymann, MA; Lin, E; Roman, C; Takahashi, Y; Tse, MM | 1 |
| Bhatnagar, A; Bolli, R; Liu, SQ; Shinmura, K; Takano, H; Tang, XL; Wang, Y; Xuan, YT | 1 |
| Bing, RJ; Johnson, PE; Kakar, NR; Vina, ER; Yamamoto, T | 1 |
| Bolli, R; Kodani, E; Shinmura, K; Takano, H; Tang, XL; Xuan, YT | 1 |
| Akmal, Y; Ang, JG; Beharry, K; Modanlou, HD; Nishihara, KC; Ozaki, N | 1 |
| Akmal, Y; Asrat, T; Beharry, K; Hausman, N; Nishihara, K | 1 |
| Alcindor, D; Kersten, JR; Krolikowski, JG; Pagel, PS; Warltier, DC | 1 |
| Busse, R; Falck, JR; Fleming, I; Michaelis, UR; Schmidt, R | 1 |
| Busse, R; Fleming, I; Kohlstedt, K | 1 |
| Bjorling, DE; Calamon-Dixon, JL; Jerde, TJ; Nakada, SY | 1 |
| Frölich, JC; Gutzki, FM; Marhauer, V; Stichtenoth, DO; Tsikas, D | 1 |
| Lin, GC; Liu, ZG; Lu, ZH; Mei, QB; Meng, JR; Shi, YX; Xiong, XY; Zhang, BL; Zhou, YM | 1 |
| Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C | 1 |
| Baker, LD; Breitner, JC; Milne, G; Montine, TJ; Sonnen, JA | 1 |
| Alamuddin, N; Cen, L; Fitzgerald, GA; Lawson, JA; Propert, KJ; Skarke, C | 1 |
| Jeong, SH; Jung, Y; Kim, H; Kim, W; Lee, Y; Yoon, JH | 1 |
| Hong, S; Jung, Y; Kim, W; Lee, Y; Park, H; Yoon, JH; Yum, S | 1 |
| Del Valle-Mondragón, L; Guzmán-Hernández, EA; Ibarra-Barajas, M; Pastelín-Hernández, G; Sánchez-Mendoza, MA; Villalobos-Molina, R | 1 |
| Jeong, S; Jung, Y; Kim, J; Kim, MS; Kim, W; Lee, S; Lee, Y; Nam, J; Yoo, JW | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
4 trial(s) available for celecoxib and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Body Weight; Celecoxib; Creatinine; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Diuretics; Female; Furosemide; Humans; Indomethacin; Kidney; Potassium; Prostaglandins; Pyrazoles; Renin; Sodium; Sulfonamides; Thromboxane B2 | 2005 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2 | 2007 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Therapy, Combination; F2-Isoprostanes; Female; Humans; Male; Naproxen; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome | 2010 |
Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Asian; Black People; Carbonic Anhydrase Inhibitors; Cardiovascular Diseases; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Epoprostenol; Female; Furans; Humans; Male; Middle Aged; Prostaglandin Antagonists; Prostaglandins; Pyrazoles; Risk Assessment; Sulfonamides; Thromboxane B2; White People; Young Adult | 2012 |
19 other study(ies) available for celecoxib and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Endotoxemia; Endotoxins; Hypotension; Isoenzymes; Male; Multiple Organ Failure; Nitrates; Nitrites; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Sulfonamides | 1998 |
Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.
Topics: 6-Ketoprostaglandin F1 alpha; Amidines; Analysis of Variance; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylamines; Celecoxib; Crotonates; Cyclooxygenase 2; Dexamethasone; Diclofenac; Enzyme Inhibitors; Hydroxybutyrates; Isoenzymes; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitriles; Nitrites; Nitrogen Dioxide; omega-N-Methylarginine; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Toluidines | 1998 |
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Monocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2 | 1999 |
Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Ductus Arteriosus; Epoprostenol; Female; Hemodynamics; In Vitro Techniques; Indomethacin; Isoenzymes; Nitrobenzenes; Nitroprusside; Oxygen; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pulmonary Artery; Pyrazoles; Sheep; Sulfonamides; Vasoconstriction; Vasodilator Agents | 2000 |
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprost; Gene Expression Regulation, Enzymologic; Ischemic Preconditioning; Isoenzymes; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Rabbits; Sulfonamides; Transcription, Genetic | 2000 |
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Heart; Isoenzymes; Male; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Sulfonamides; Thromboxane A2 | 2001 |
Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Benzamides; Benzylidene Compounds; Celecoxib; Consciousness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Heart Rate; Ischemic Preconditioning, Myocardial; Isoenzymes; Male; Myocardial Infarction; Myocardial Stunning; Myocardium; Naltrexone; Narcotic Antagonists; Nitrobenzenes; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Receptors, Opioid, delta; Sulfonamides | 2002 |
Differential regulation of prostacyclin and thromboxane by dexamethasone and celecoxib during oxidative stress in newborn rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Animals, Newborn; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dexamethasone; Dinoprost; Epoprostenol; F2-Isoprostanes; Hyperoxia; Oxidative Stress; Pyrazoles; Rabbits; Sulfonamides; Thromboxane B2 | 2002 |
Antenatal administration of celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, appears to improve placental perfusion in the pregnant rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Isoenzymes; Nitric Oxide; Organ Size; Perfusion; Placenta; Pregnancy; Pregnancy, Animal; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rabbits; Sulfonamides; Thromboxane B2; Time Factors | 2003 |
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anesthetics, Inhalation; Animals; Aspirin; Celecoxib; Coronary Circulation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diazoxide; Dogs; Hemodynamics; Ischemic Preconditioning, Myocardial; Isoenzymes; Isoflurane; Membrane Proteins; Myocardial Infarction; Myocardium; Potassium Channels; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; 8,11,14-Eicosatrienoic Acid; Amino Acid Sequence; Aryl Hydrocarbon Hydroxylases; Carbazoles; Celecoxib; Cells, Cultured; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; DNA, Antisense; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Epoprostenol; Humans; Indoles; Membrane Proteins; Molecular Sequence Data; Morphogenesis; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Recombinant Fusion Proteins; RNA, Messenger; Stress, Mechanical; Sulfaphenazole; Sulfonamides; Transcription Factors; Transduction, Genetic; Umbilical Veins | 2005 |
Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; Amino Acid Substitution; Angiotensin-Converting Enzyme Inhibitors; Animals; Anthracenes; Aorta; Binding, Competitive; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Humans; JNK Mitogen-Activated Protein Kinases; Lung; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation, Missense; Oligodeoxyribonucleotides; Peptidyl-Dipeptidase A; Phosphorylation; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Prostaglandins I; Protein Processing, Post-Translational; Pyrazoles; Ramipril; Recombinant Fusion Proteins; Signal Transduction; Sulfonamides; Sus scrofa; Thromboxane A2; Transcription Factor AP-1; Transcription, Genetic; Transfection; Umbilical Veins | 2005 |
Celecoxib inhibits ureteral contractility and prostanoid release.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase Inhibitors; Depression, Chemical; Dimethyl Sulfoxide; Dinoprost; Dinoprostone; Gas Chromatography-Mass Spectrometry; Humans; Indomethacin; Muscle Contraction; Nitrobenzenes; Prostaglandin Antagonists; Prostaglandin D2; Prostaglandins; Pyrazoles; Secretory Rate; Sulfonamides; Sus scrofa; Thromboxane A2; Tumor Necrosis Factor-alpha; Ureter; Ureteral Obstruction | 2005 |
Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Topics: 6-Ketoprostaglandin F1 alpha; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Macrophages; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Naphthalenes; Pyrazoles; Sulfonamides | 2005 |
Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Aspartic Acid; Cecum; Celecoxib; Chemistry Techniques, Synthetic; Chromatography, High Pressure Liquid; Colon; Cyclooxygenase 2 Inhibitors; Drug Delivery Systems; Drug Stability; Glutamates; Intestinal Absorption; Male; Molecular Structure; Prodrugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Solubility; Sulfonamides; Tissue Distribution | 2012 |
Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cell Line; Colitis; Colon; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation; Humans; Male; Mice; Prodrugs; Pyrazoles; Rats; Sulfonamides; Trinitrobenzenesulfonic Acid | 2014 |
Early co-expression of cyclooxygenase-2 and renin in the rat kidney cortex contributes to the development of N(G)-nitro-L-arginine methyl ester induced hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Captopril; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Gene Expression Regulation; Hypertension, Renal; Kidney Cortex; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptide Fragments; Random Allocation; Rats, Wistar; Renin; RNA, Messenger | 2015 |
Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Animals; Buffers; Cecum; Celecoxib; Chemistry, Pharmaceutical; Colon; Cyclooxygenase 2 Inhibitors; Dextrans; Drug Carriers; Drug Stability; Glutamates; Hydrogen-Ion Concentration; Intestinal Absorption; Intestine, Small; Male; Prodrugs; Rats, Sprague-Dawley; Technology, Pharmaceutical | 2015 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |